EUVIMEDEUVIMED entdecken
Open Access

Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer

Paolo Tarantino iD, Do Lee, Julia Foldi iD, Pamela R Soulos, Cary P Gross iD, Tess O'Meara iD, Thomas Grinda iD, Stefania Morganti iD, Adrienne G Waks, Eric P Winer iD, Nancy U Lin iD, Ian E Krop iD und 3 weitere

JNCI: Journal of the National Cancer Institute · 01.11.2025 · 117 (11) · 2327-2335

DOI: 10.1093/jnci/djaf220 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 14.08.2025. Verfasst von Paolo Tarantino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Camptothecin, Immunoconjugates. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, METAvivor Early Career Investigator, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available to guide treatment after exposure to T-DXd.

Methods

We utilized a nationwide electronic health record-derived, deidentified database to review data of patients with MBC who initiated T-DXd between December 2019 and December 2023 and who received an additional line of treatment after T-DXd. Tumors were categorized as HER2-positive if ever positive before T-DXd, and HER2-negative if never HER2-positive before T-DXd. We compared real-world progression-free survival (rwPFS) and overall survival for post-T-DXd treatments using the Kaplan-Meier method and the log-rank test.

Results

We identified 793 patients receiving a post-T-DXd treatment. Post-T-DXd treatment outcomes differed significantly by MBC subtype: median rwPFS was 4.6 months for HER2-positive, 3.4 months for hormone receptor- (HR)-positive/HER2-negative, and 2.8 months for triple-negative MBC (P < .001). Outcomes with post-T-DXd treatments also varied significantly according to treatment regimen (P < .001). Among patients with HER2-positive MBC, median rwPFS ranged from 6.7 months with endocrine treatment regimens to 2.6 months with sacituzumab govitecan (SG). Among patients with HR-positive/HER2-negative MBC, rwPFS ranged from 5.9 months with eribulin to 2.6 months with SG. Among patients with triple-negative MBC, poor outcomes (rwPFS ≤3 months) were observed with most treatment regimens, including SG (3 months), eribulin (2 months), and multiagent chemotherapy (2.5 months).

Conclusions

Outcomes of post-T-DXd treatments differ significantly by MBC subtype and type of regimen administered. The use of SG immediately after T-DXd was associated with relatively short rwPFS across subtypes, highlighting some degree of cross-resistance with T-DXd. Trial Registration N/A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabBreast NeoplasmsCamptothecinImmunoconjugatesAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAgedErb-b2 Receptor Tyrosine KinasesAdultNeoplasm MetastasisTreatment OutcomeAntineoplastic Agents, ImmunologicalProgression-Free SurvivalAged, 80 and over

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesCamptothecinImmunoconjugatesAntineoplastic Agents, Immunologicaltrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Harvard Medical School, Boston, MA, United States.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.
  • Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT, United States.

ORCID-Profile: Paolo Tarantino, Julia Foldi, Cary P Gross, Tess O'Meara, Thomas Grinda, Stefania Morganti, Eric P Winer, Nancy U Lin, Ian E Krop, Sara M Tolaney, Sarah Sammons

Förderung

  • NCATS NIH HHS
  • METAvivor Early Career Investigator
  • AstraZeneca
  • Elaine and Eduardo Saverin Foundation
  • Terri Brodeur Breast Cancer Foundation

Zitieren

APA

Tarantino, P., Lee, D., Foldi, J., Soulos, P. R., Gross, C. P., O'Meara, T., Grinda, T., Morganti, S., Waks, A. G., Winer, E. P., Lin, N. U., Krop, I. E., Tolaney, S. M., Sammons, S., & Lustberg, M. (2025). Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. JNCI: Journal of the National Cancer Institute, 117(11), 2327-2335. https://doi.org/10.1093/jnci/djaf220

Vancouver

Tarantino P, Lee D, Foldi J, Soulos PR, Gross CP, O'Meara T, et al. Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer. JNCI: Journal of the National Cancer Institute. 2025;117(11):2327-2335. doi:10.1093/jnci/djaf220

BibTeX
@article{Tarantino2025,
  author = {Tarantino, Paolo and Lee, Do and Foldi, Julia and Soulos, Pamela R and Gross, Cary P and O'Meara, Tess and Grinda, Thomas and Morganti, Stefania and Waks, Adrienne G and Winer, Eric P and Lin, Nancy U and Krop, Ian E and Tolaney, Sara M and Sammons, Sarah and Lustberg, Maryam},
  title = {Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  volume = {117},
  number = {11},
  pages = {2327--2335},
  doi = {10.1093/jnci/djaf220}
}
Kostenlos starten →